Table 2.
Associations between HUA and sUA at baseline with new-onset CKD.
| N | No of Events (%) | Model 1 | Model 2 | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | |||
| HUA at Baseline | ||||||
| Non-HUA | 24,553 | 933 (3.80%) | 1.00 | 1.00 | ||
| HUA | 3869 | 279 (7.21%) | 1.70 (1.48–1.93) | <0.001 | 1.28 (1.12–1.47) | <0.001 |
| sUA (μmol/L) | ||||||
| Q1 (≤285) | 7024 | 192 (2.73%) | 1.00 | 1.00 | ||
| Q2 (266–318) | 7087 | 260 (3.67%) | 1.22 (1.01–1.47) | 0.036 | 1.03 (0.85–1.25) | 0.738 |
| Q3 (319–374) | 7091 | 309 (4.36%) | 1.46 (1.22–1.74) | <0.001 | 1.04 (0.85–1.27) | 0.705 |
| Q4 (≥375) | 7220 | 451 (6.25%) | 2.02 (1.70–2.39) | <0.001 | 1.24 (1.01–1.51) | 0.038 |
| p trend | <0.001 | <0.001 | ||||
Model 1 was not adjusted for any covariates. Model 2 was adjusted for age (<45 years, 45–64 years, ≥65 years), gender (male, female), BMI (<24.0 kg·m−2, 24.0–27.9 kg·m−2, ≥28 kg·m−2), smoking status (non-smoker, smoker, ex-smoker), drinking status (non-drinker, drinker, ex-drinker), diabetes (no, yes), hypertension (no, yes), TG (≤1.20 mmol/L, 1.21–2.00 mmol/L, ≥2.01 mmol/L) at baseline. Q1–Q4 referred to the quartiles of serum uric acid grouped according to the quartiles of the non-CKD participants, respectively. The median of each group was included in the regression model as a continuous variable to calculate the p value for the test of trend. HUA, hyperuricemia; sUA, serum uric acid; SBP, systolic blood pressure; CKD, chronic kidney disease; HR, hazard ratio; CI, confidence interval.